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Background: Diabetes mellitus is associated with a high risk of cardiovascular disease. Carotid 
intima-media thickness (CIMT) is increasingly used as a surrogate marker for atherosclerosis. 
Its use relies on its ability to predict future clinical cardiovascular end points.
Methods: This review examines the evidence linking CIMT as a surrogate marker of vascular 
complications in people with type 1 and type 2 diabetes. We have also reviewed the various 
treatment strategies which have been shown to influence CIMT.
Conclusions: CIMT measurement is an effective, noninvasive tool which can assist in 
 identifying people with diabetes who are at higher risk of developing microvascular and 
macrovascular complications. It may also help to evaluate the effectiveness of various treatment 
strategies used to treat people with diabetes.
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Cardiovascular disease in diabetes
Diabetes mellitus is associated with a high risk of cardiovascular disease (CVD) which 
is the most common cause of mortality in people with diabetes.1,2 CVD accounts for 
more than 80% of deaths in people with diabetes.3,4 A two- to fourfold increased risk 
of CVD in people with diabetes compared with the background population has been 
reported by various research groups.5,6
The risk of stroke is increased 150% to 400% in people with diabetes.7–9 In the 
 Multiple Risk Factor Intervention Trial (MRFIT), people taking medications for 
diabetes were three times as likely to develop cerebrovascular disease compared with 
those not receiving medications for diabetes.5 In type 1 diabetes, the prevalence of cere-
brovascular disease has varied from 4% to 21% depending on the duration of diabetes 
and the population studied10–13 and was found to confer an increased risk of stroke 
(odds ratio 11.6; 95% confidence interval [CI]: 1.2–115.2) in a study of 201 people 
younger than 55 years who developed a stroke due to cerebral infarction.14
Diabetes is also associated with increased incidence and extent of peripheral  arterial 
disease.15 Thus, not only does atherosclerosis develop at a younger age in people 
with diabetes, it is also more diffuse and severe than that found in people without 
diabetes. People with diabetes have a two- to fourfold increased risk of peripheral 
arterial disease.16
Ultrasonographic assessment of endothelial function of brachial artery 
 flow-mediated dilatation and evaluation of carotid intima-media thickness (CIMT) 
have been used as a surrogate marker of CVD in people with diabetes.
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Endothelial function and CVD
Endothelial dysfunction precedes the development of 
atherosclerosis and is believed to play a central role in its 
pathophysiology. Ludmer and colleagues first demonstrated 
impaired endothelial-dependent vasodilatation in the pres-
ence of atherosclerosis.17 Endothelial dysfunction in the 
peripheral vessels are modestly correlated with the endothe-
lial function in the coronary vessels.18,19
Flow-mediated dilatation in response to postocclusive 
reactive hyperemia has been used to noninvasively assess 
endothelial function in the peripheral vascular system.20 
Brachial flow-mediated dilation (FMD) has been found to 
be inversely associated with CIMT.21–23 In the Cardiovascular 
Risk in Young Finns Study, FMD and CIMT were measured 
in 2109 healthy people aged 20 to 39 years.21 Individuals 
were classified into subgroups as those with impaired, 
intermediate, and enhanced FMD if the FMD was 10th 
percentile, between 10th to 90th percentile, and 90th 
percentile, respectively. The number of cardiovascular risk 
factors was correlated with increased CIMT in those indi-
viduals with impaired or intermediate FMD, but not in those 
with enhanced FMD, which suggests a crucial link between 
CIMT and endothelial dysfunction, with the latter appearing 
to be essential for cardiovascular risk factors to be able to 
contribute to atherosclerosis in the arterial wall.
CIMT
CIMT is the area of tissue starting at the luminal edge of the 
artery and ending at the boundary between the media and the 
adventitia (Figure 1).24 It is measured using B-mode ultra-
sound as the composite thickness of the intima and media. 
The ‘double-line pattern’ is thus the distance between the 
two echogenic lines that represent the lumen–intima inter-
face and the media–adventitia interface. CIMT in healthy 
middle-aged adults measures 0.6 to 0.7 mm and greater than 
1.20 mm is considered abnormal.25 CIMT is age-dependent 
and increases at a rate of 0.005 to 0.010 mm/year.26 Thus, in 
younger individuals, a CIMT of greater than 1.00 mm would 
be considered abnormal.27
Iglesias del Sol and colleagues measured the CIMT at the 
common carotid, bifurcation, internal carotid, and combined 
CIMT and found that the area under the receiver operator 
characteristic (ROC) curves, as a predictor of coronary artery 
disease, for these segments were 0.67 (95% CI: 0.61–0.73), 
0.69 (0.63–0.75), 0.67 (0.61–0.73), and 0.67 (0.61–0.73), 
respectively.28 Thus the authors concluded that all the mea-
surement sites had the same ability to predict future cardio-
vascular events.
Limitations of CIMT measurement
There is no standardized protocol for measurement of CIMT. 
This can result in inaccurate measurements of the progression 
or regression of CIMT during the follow up studies or in the 
assessment of any therapeutic interevention on the measured 
CIMT. Since the implementation of the edge detection soft-
ware there has been improved reproducibility and reduced 
interobserever variation.29
Different portions of the carotid artery have been used 
to measure the CIMT, common carotid, bifurcation, internal 
carotid, and combined CIMT which may influence the value 
of the measured CIMT. However in the study by Iglesias 
del Sol and colleagues CIMT was measured at the common 
carotid, bifurcation, internal carotid, and combined CIMT 
and they found that all the measurement sites had the same 
ability to predict future cardiovascular events.28
Measurement of CIMT involves a combined measure 
of the intimal and medial layer of the arterial wall, whereas 
the atherosclerotic process is restricted in the intimal layer, 
particularly in its early phase of atherosclerosis. Further-
more, CIMT is only an indirect assessment of the possible 
atherosclerotic burden in the coronary artereries which is 
the commonest cause of cardiovascular death. In a system-
atic review, Bots and colleagues reviewed 34 studies on the 
relationship of CIMT to coronary atherosclerosis. Thirty 
of these studies showed a modest positive relationship, the 
magnitude of which was similar to that found in autopsy 
studies. The modest relationship between CIMT and coronary 
Figure 1 Carotid intima-media thickness measured at the far wall of the common 
carotid artery using the double-line pattern.
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atherosclerosis most likely reflects variability in atheroscle-
rosis development between the vascular beds rather than 
limitations of CIMT measurements.30
Lastly, measured CIMT is not only a reflection of the 
atherosclerotic burden in the carotid arteies but also reflects 
age-related changes, and it is imperative that the age of an 
individual is taken into account when CIMT is measured.
CIMT – ultrasound vs histology
Ultrasonographic measurements of CIMT compared with 
histological measurements at the far-wall have been found 
to provide an accurate estimation of the IMT.31–33 Pignoli and 
colleagues compared pathological findings in vitro or in situ 
at autopsy with ultrasonographic measurement of intima-
media thickness (IMT) of the aorta and the common carotid 
arteries.34 The authors found an error of less than 20% for 
measurements in three-quarters of normal and pathological 
aortic walls. In addition, no significant difference was found 
between the ultrasonographic measurement in the common 
carotid arteries evaluated in vitro and that determined by this 
method in vivo in young subjects indicating that ultrasonog-
raphy represents a useful approach for the measurement of 
IMT in human arteries in vivo.
CIMT and CVD
CIMT is a surrogate marker of atherosclerosis and provides 
a noninvasive method for the risk assessment of CVD.35–38 
It is a strong predictor of future cardiovascular events and is 
associated with conventional markers of cardiovascular risk 
such as age, diabetes and serum cholesterol.39,40
CIMT is a well-established index of atherosclerosis 
that correlates with prevalent and incident coronary artery 
disease41,42 and stroke.43,44 Studies have shown a relation-
ship between atherosclerosis in the carotid and coronary 
arteries.45,46 Furthermore, statistically significant correlations 
(range 0.3–0.5) between CIMT and coronary atherosclerosis, 
the latter based on a coronary angiogram, coronary calcium 
studies, or intravascular ultrasound, have been noted.30,47,48
CIMT is associated with cardiovascular risk factors49 
and both prevalent and incident coronary artery disease and 
stroke.41,44,50,51 Furthermore, the progression of CIMT is influ-
enced by cardiovascular risk factors and is directly related to 
the risk of future cardiovascular events.48,52 CIMT has therefore 
become a valuable research tool in clinical trials in the assess-
ment of therapeutic agents directed against atherosclerosis. 
Thus, on account of these characteristics, CIMT has been used 
as an intermediate end point to assess the therapeutic efficacy 
of various interventions in a number of clinical studies.53
In a meta-analysis of 37197 individuals followed-up for 
a mean duration of 5.5 years, Lorenz and colleagues found 
that a 0.1 mm absolute difference in CIMT was associ-
ated with a relative risk of myocardial infarction of 1.15 
(95% CI: 1.12–1.17) and a relative risk of stroke of 1.18 
(95% CI: 1.16–1.21).54
Studies have also demonstrated association between 
cardiovascular risk and increased CIMT in people with type 
1 diabetes.55–57
In the recent Multi-Ethnic Study of Atherosclerosis 
(MESA), coronary artery calcium (CAC) scoring was 
 compared to CIMT in predicting CVD incidence in 
6698 individuals aged 45 to 84 years who were asymptomatic 
and free of CVD at baseline. The study found that compared 
with CIMT, CAC was more strongly associated with incident 
CVD in the overall population. In contrast, CIMT was found 
to be a modestly better predictor of stroke than CAC scoring, 
which could be perhaps the result of the difference between 
vascular territories targeted by the two measures.58 Although 
the CAC estimation was a better predictor of incident CVD 
in this study, measurement of CAC has a major disadvantage 
of exposing people to ionizing radiation.
CIMT and cardiovascular  
risk factors
A number of risk factors have been associated with the devel-
opment of atherosclerosis in the carotid arteries. The findings 
that the risk factors that predict CIMT are those that also 
predict coronary artery disease is concordant with the 
evidence that atherosclerosis is a diffuse disease.59 These risk 
factors include increasing age,60–62 male sex,63 smoking,61–64 
blood pressure,61–64 measures of adiposity such as body 
mass index,60,65 waist-to-hip ratio,66 sedentary lifestyle,66 
family history,67 ethnicity,68 and the presence of diabetes or 
glucose intolerance.63,64,66 CIMT has also been reported to be 
associated with serum cholesterol,60–64 triglyceride levels,60 
high-density lipoprotein (HDL) cholesterol,60–64 low-density 
lipoprotein LDL cholesterol,65 high-sensitivity C-reactive 
protein,69 and asymmetric dimethylarginine.70
A number of studies have evaluated the determinants of 
change in CIMT over time.71 The Atherosclerosis Risk in 
Communities (ARIC) study among 15,792 individuals aged 
45 to 64 years reported statistically significant associations 
of change in CIMT with baseline diabetes, current smoking, 
HDL cholesterol, pulse pressure, white blood cell count, and 
fibrinogen during the follow-up from 1987 to 1998.72 Further-
more, significant associations were found between change in 
CIMT and change in LDL cholesterol, and serum triglyceride 
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and with onset of diabetes and hypertension, during the 
follow-up. Data from the Rotterdam study among 3409 men 
and women aged 55 years, in which CIMT was measured 
twice 6.5 years apart, indicated that moderate to severe 
progression of CIMT (above the 60th and 90th percentile of 
CIMT, respectively) was related to age, body mass index, 
male sex, current smoking, systolic blood pressure, and the 
presence of hypertension.73 Lipid levels, however, were not 
related to increased progression of CIMT. Recently, the 
Carotid Atherosclerosis Progression Study among 3383 men 
and women found that age, male sex, hypertension, presence 
of diabetes, and smoking were related to increased progres-
sion of internal CIMT over 3 years, whereas no relation was 
found for common CIMT.74
These studies suggest that CIMT is increased in the pres-
ence of risk factors associated with CVD and furthermore, 
the progression of CIMT is associated with cardiovascular 
risk factors.
CIMT in people with type 1 diabetes
Several research groups have found an association between 
type 1 diabetes and CIMT.55,57,75–79 Yamasaki and colleagues 
evaluated CIMT to assess the carotid arteries in 105 young 
patients with type 1 diabetes, 529 patients with type 2 diabetes, 
and 104 nondiabetic healthy people subjects. People with 
type 1 diabetes had significantly higher CIMT than healthy 
controls, whereas people with noninsulin-dependent diabetes 
showed CIMT values equivalent to those in normal adults. 
They reported that on multiple regression analysis CIMT in 
insulin-dependent diabetes patients was positively related to 
the duration of diabetes as well as to age. No other possible 
risk factors, such as serum total cholesterol level, serum HDL 
cholesterol level, LDL cholesterol, serum triglycerides, serum 
lipoprotein(a) level, or systolic or diastolic blood pressure 
showed any significant correlations. However, non-HDL 
cholesterol, smoking, and systolic hypertension were inde-
pendently responsible for increases in CIMT values of type 
2 diabetes patients as well as age and duration of diabetes.55 
Larsen and colleagues reported higher CIMT values in people 
with type 1 diabetes. They also reported a significant asso-
ciation between the glycosylated hemoglobin (HbA
1c
) levels 
and CIMT (r2  0.77; P  0.0001 when adjusted for age) in 
women with type 1 diabetes, though no such correlation was 
seen in men. Among women, a significant association was 
also found between CIMT and the percentage of coronary 
vessel area stenosis, measured by intravascular ultrasound.57 
The Epidemiology of Diabetes Interventions and Com-
plications (EDIC) Research Group found that  traditional 
 cardiovascular risk factors including increasing age, smok-
ing, and LDL cholesterol were related to CIMT.80 In a further 
study, 40 people aged 11 to 30 years with duration of type 1 
diabetes of 3 to 25 years compared with 40 healthy controls 
confirmed a higher CIMT in the cohort with diabetes (0.6 p 0.1 
vs 0.4 p 0.1 mm; P  0.001). CIMT was found to correlate 
with age (r  0.76; P  0.001), body mass index (r  0.82; 
P  0.001), duration of diabetes (r  0.66; P  0.001), systolic 
blood pressure (r  0.82; P  0.001), diastolic blood pressure 
(r  0.83; P  0.001), HbA
1c
 (r  0.40; P  0.004) and HDL 
(r  0.88; P  0.001).81
In an observational longitudinal study over a period of 
2.5 years of 102 people with type 1 diabetes, CIMT increased 
by a mean of 0.033 mm per year.82 Furthermore, CIMT was 
found to correlate with age (r  0.34; P  0.01), diabetes 
duration (r  0.25; P  0.05) and systolic blood pressure 
(r  0.28; P  0.05) at baseline. In addition, the maximum 
change in CIMT was observed in people who had hyper-
tension and nephropathy. CIMT has been reported to be 
increased in children with type 1 diabetes compared with 
healthy controls.83,84 Atherogenic risk factors such as systolic 
blood pressure, duration of diabetes, and body weight were 
positively correlated with CIMT in children and adolescents 
with type 1 diabetes.84
In type 1 diabetes, the increase in CIMT has been shown 
to start in childhood and adolescence by some55,75 but not all 
studies.85,86 In a recent study of young children with type 1 
diabetes with modest glycemic control, Margeirsdottir and 
colleagues reported increased CIMT despite intensive 
insulin treatment.86 In another study, Schwab and colleagues 
reported increased CIMT in the pediatric population (body 
mass index), markers of sustained inflammation, endothelial 
dysfunction, and fibrinolytic activity were increased in dia-
betic versus nondiabetic children, none of these measures 
being significant correlates of CIMT. The authors reported 
that that in well-controlled type 1 diabetes, systolic blood 
pressure may be of greater importance than dyslipidemia in 
early atherogenesis.84
In a study of young people with type 1 diabetes without 
known macrovascular disease or microalbuminuria, CIMT 
was found to be increased by 25% (P  0.001) in type 1 
diabetes compared with healthy controls.22
CIMT in people with impaired 
glucose tolerance and type 2 diabetes
People with impaired glucose tolerance (IGT) have been shown 
to have endothelial dysfunction and are at increased risk of 
CVD. CIMT has been observed to be increased in people 
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who would subsequently develop diabetes.87 Yamasaki and 
colleagues have reported that people with IGT had increased 
CIMT and there was no difference in CIMT among the people 
with IGT and age- and sex-matched people with type 2 dia-
betes.88 In another study postchallenge glucose levels were 
strongly associated with CIMT in people at risk of diabetes or 
who were at the early stages of type 2 diabetes.89 These studies 
suggest that people with IGT or at the early stages of type 2 
diabetes are already at increased risk of CVD.
A review of 21 studies including 24,111 people with type 
2 diabetes (n  4019) and IGT (n  1110) found that CIMT 
was higher in individuals with diabetes compared to the 
healthy controls. Compared with healthy controls, CIMT was 
increased in individuals with type 2 diabetes by 0.13 (95% CI: 
0.12–0.14) mm and by 0.04 (95% CI: 0.01–0.07) mm in indi-
viduals with IGT.90 Other research groups have found CIMT 
to be increased in type 2 diabetes.91–93 Furthermore, CIMT has 
been demonstrated to be higher in people with diabetes and 
macrovascular disease.94 In a prospective study, Bernard and 
colleagues reported that CIMT provides a similar predictive 
value for coronary events compared with the Framingham score, 
and suggested that the combination of these two indexes would 
significantly improve risk prediction in these patients.95
A study was conducted in 98 people with type 2 diabetes 
with no known CVD to ascertain the clinical usefulness of 
CIMT in identifying those individuals in whom the single-
photon emission computed tomography myocardial perfusion 
imaging is abnormal.96 An increased CIMT was found to be 
significantly related to the presence and extent of abnormal 
myocardial perfusion. In another study, the usefulness of 
CIMT in predicting the presence of coronary artery disease, 
as detected by noninvasive computed tomographic coronary 
angiography, in asymptomatic people with diabetes was 
investigated (n  150, aged 50 p 13 years, 83 men).97 Mean 
CIMT increased from 0.58 p 0.08 mm in those with normal 
coronary arteries (n  59, 39%), to 0.67 p 0.12 mm in those 
with nonobstructive atherosclerosis (n  54, 36%) and 
0.75 p 0.12 mm in those with obstructive stenosis defined 
as a 50% narrowing of the luminal diameter (n  36, 25%; 
P  0.01). Furthermore, a cut-off value of 0.67 mm for 
CIMT predicted obstructive coronary atherosclerosis with 
a sensitivity of 85% and specificity of 72%.
CIMT has been shown to be a predictor of incidence 
and recurrence of stroke.44,98 Similarily, increased CIMT has 
been found to be associated with increased risk of ischemic 
stroke in people with type 2 diabetes.99,100 Increased CIMT 
and plaque score have been demonstrated to correlate with 
acute ischemic stroke in patients with type 2 diabetes.99
Along with hyperglycemia, other metabolic factors 
 associated with diabetes that are known to increase cardiovas-
cular risk including obesity, insulin resistance, hypertension, 
hyperlipidemia, and increased inflammatory state have all been 
shown to contribute to progression of CIMT in people with 
diabetes.98,99,101,102 The Relationship between Insulin Sensitivity 
and Cardiovascular disease (RISC) study conducted in 1326 
European nondiabetic healthy individuals aged 30 to 60 years 
measured CIMT and its associations with fasting insulin 
and insulin resistance by performing standard oral glucose 
tolerance tests and hyperinsulinemic euglycemic clamps.103 
CIMT was statistically significantly associated with fasting 
insulin in healthy people. In contrast, Kong and colleagues 
studied normotensive individuals with type 2 diabetes and 
found no association between CIMT and fasting insulin or 
insulin sensitivity as assessed with an insulin-modified fre-
quently sampled intravenous glucose tolerance test.104
Thus CIMT is increased in people with diabetes from a 
young age. The progression of CIMT is associated with the 
traditional risk factors of CVD such as hypertension and 
dyslipidemia.
CIMT and microvascular 
complications
CIMT has been shown to be increased in people with type 
1 diabetes and retinopathy.105,106 In a cross-sectional study, 
the severity of retinopathy was found to be associated with 
CIMT (odds ratio per 0.1 mm CIMT 1.09 [95% CI: 1.01–1.17; 
P  0.01]),107 consistent with studies in people with type 2 
diabetes.108,109 In a recent study, Vigili de Kreutzenberg and 
colleagues studied the association between diabetic retinopa-
thy and CIMT in people with type 2 diabetes. The authors 
reported that retinopathy either alone or in combination with 
nephropathy, is independently associated with CIMT in people 
with type 2 diabetes, and the severity of microangiopathy cor-
relates with severity of carotid atherosclerosis.110 In another 
study of people with type 1 diabetes, the association between 
CIMT and microangiopathic complications including retin-
opathy or nephropathy was reported.111
Effect of therapeutic interventions 
on CIMT in people with diabetes
Blood glucose lowering in type 1  
and type 2 diabetes and CIMT
A 16-week intensive lifestyle modification program and 
subsequent monthly meetings during the 6-month study period 
in 58 people with type 2 diabetes was found to be associated 
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with a significantly reduced mean CIMT progression 
after 6 months (0.040 p 0.136 vs 0.083 p 0.167 mm; 
P  0.007).112 Furthermore, changes in HbA
1c
 (r  0.34; 
P  0.028), fasting plasma glucose (r  0.31; P  0.045), and 
2-hour postprandial plasma glucose (r  0.37; P  0.015) 
correlated with the mean CIMT change after adjustment for 
age and sex. Thus, in addition to improved blood glucose 
control, lifestyle measures have decreased progression of 
CIMT. Data analyses from 11 studies (n  1578) in people 
with type 2 diabetes and IGT evaluated the effect of inter-
ventions on change in CIMT. The annual increase of CIMT 
was 0.034 mm/y (95% CI: 0.029–0.039) in people with type 
2 diabetes without any specific interventions in which mean 
HbA
1c
 was 7.86%. A significant close correlation of HbA
1c
 
with rate of CIMT change was found (r  0.35; P  0.01). 
Agents for lowering of blood glucose, platelet activation, 
or blood pressure significantly reduced the CIMT increase, 
independent of blood glucose control.113
As part of the EDIC study, the long-term follow-up of 
the Diabetes Control and Complications Trial (DCCT), 
1229 people with type 1 diabetes (intensive blood glucose 
lowering arm n  618; conventional blood glucose lowering 
arm n  611) underwent internal and common CIMT mea-
surements in 1994 to 1996 and again in 1998 to 2000.56 
Although CIMT was not statistically significantly different 
between the people with diabetes and the healthy controls 
after 1 year of follow-up in the EDIC study,114 CIMT was 
significantly greater in people with type 1 diabetes compared 
with the healthy controls after a follow-up of 6 years in the 
EDIC study.56 Furthermore, the progression of CIMT in the 
common carotid artery was significantly less in the group 
that received intensive therapy than in the group that received 
conventional therapy during the DCCT (0.032 vs 0.046 mm; 
P  0.01) after adjustment for other risk factors. Factors that 
were associated with progression of CIMT were age, the 
EDIC base-line systolic blood pressure, smoking, ratio of 
LDL to HDL cholesterol, urinary albumin excretion rate, and 
the mean HbA
1c
 during the DCCT.
A Japanese study randomized individuals with type 2 
diabetes without known macrovascular disease to pioglitazone 
with or without other oral glucose-lowering agents (n  89) 
or other oral glucose-lowering agents excluding thiazolidene-
diones (n  97), with treatment goal of HbA
1c
 6.5%. The 
authors found that pioglitazone induced regression of mean 
CIMT from 0.839 p 0.1873 to 0.780 p 0.1571 mm; P  0.002), 
although the between-group difference did not reach statistical 
significance.115
The Pioglitazone in the Prevention of Diabetes (PIPOD) 
study assessed the effects of pioglitazone in Hispanic women 
with prior gestational diabetes mellitus who had previously 
completed the troglitazone in the Prevention of Diabetes 
(TRIPOD) study.116–118 Thirty-one women came to PIPOD 
from the troglitazone arm while 30 came from the placebo 
arm of TRIPOD. During the 3-year follow-up, the 31 women 
who came to PIPOD from the troglitazone arm of TRIPOD 
were found to have a lower progression of CIMT of 38% 
during pioglitazone treatment than during troglitazone treat-
ment, although this was not statistically significant (0.0037 
vs 0.0060 mm/year; P  0.260). The progression of CIMT 
was 69% lower during pioglitazone treatment than it had been 
during placebo in the 30 women who came to PIPOD from 
the placebo arm of TRIPOD (0.0031 vs 0.0100 mm/year; 
P  0.006). The authors concluded that pioglitazone slows 
progression of CIMT in women who had been on placebo in 
the TRIPOD study and maintained a low rate of progression 
in those who had previously been treated with troglitazone. 
The low CIMT progression during treatment with the thiaz-
olidendiones was speculated to be due to PPAR-G activation 
in the vasculature and change in proinflammatory and pro-
thrombotic markers.119,120
A greater reduction in CIMT independent of improved 
glycemic control, after 12 and 24 weeks of pioglitazone treat-
ment, compared to glimeperide in 173 people with type 2 
diabetes has been reported.121 These data were later confirmed 
by Mazzone and colleagues in 462 people with type 2 diabetes 
(mean age 60 years) during a 72-week study. The authors 
found that the mean change in CIMT was less with piogli-
tazone than with glimepiride (0.001 mm vs 0.012 mm, 
respectively; difference 0.013 mm; P  0.020).122
In another study, pioglitazone, but not glibenclamide or 
voglibose, was found to reduce CIMT in people with type 
2 diabetes and diabetic nephropathy at 6- and 12-month 
follow-up.123
In the randomized, placebo-controlled, Study of 
 Atherosclerosis with Ramipril and Rosiglitazone (STARR), 
the effect of ramipril and of rosiglitazone on CIMT in 
people with IGT or impaired fasting glucose (IFG) was 
investigated.124 People with IGT and/or IFG but without CVD 
or diabetes (n  1425) were randomized to ramipril 15 mg/day 
or its placebo and to rosiglitazone 8 mg/day or its placebo with 
a 2 s 2 factorial design. The annual change of the maximum 
CIMT and the mean common CIMT were measured after 
a median follow-up of 3 years. Rosiglitazone significantly 
reduced the mean CIMT (difference 0.0043 p 0.0017 mm/y, 
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P  0.010) but not the maximum CIMT. In contrast, there 
was no statistically significant difference between the ramipril 
and placebo groups.
In another study, glibenclamide in combination with 
metformin was associated with reduced progression of CIMT 
(0.003 p 0.048 mm) compared with glibenclamide alone 
(0.064 p 0.045 mm) and gliclazide group (0.032 p 0.036 mm) 
(P  0.0001 and P  0.043 respectively).125 The annual 
progression of maximum CIMT in the gliclazide group 
(0.044 p 0.106 mm) and the glibenclamide plus metformin 
group (0.041 p 0.105 mm) was smaller than that of the gliben-
clamide group (0.114 p 0.131 mm). Attenuation of the CIMT 
progression by metformin in people with type 2 diabetes has 
been confirmed by others.126 Metformin has antithrombotic 
effects, modulates the generation of reactive oxygen species, 
and reduces systemic methylglyoxal concentration, all of which 
might contribute to the beneficial effect on CIMT.127,128
The Copenhagen Insulin and Metformin Therapy trial 
aims to assess the effect of an 18-month treatment with 
metformin versus placebo in combination with one of three 
insulin analog regimens, with CIMT being the primary 
outcome measured in 950 individuals with type 2 diabetes. 
The three insulin regimens compared are 1) insulin detemir 
before bedtime (n ^ 315 patients), 2) biphasic insulin aspart 
30 before dinner with the possibility to increase to 2 or 
4 injections daily (n ^ 315 patients), and 3) insulin aspart 
before the main meals (three times daily) and insulin detemir 
before bedtime (n ^ 315 patients).129
In the prospective, randomized, placebo-controlled, 
Study to Prevent Non-Insulin Dependent Diabetes Mellitus 
(STOP-NIDDM) trial, an A-glucosidase inhibitor, acarbose, 
delayed progression from IGT to overt type 2 diabetes and 
reduced cardiovascular events.130 A subgroup analysis of the 
STOP-NIDDM study examined the efficacy of acarbose on 
progression of CIMT in people with IGT.131 One hundred 
thirty-two individuals with IGT were randomized to placebo 
(n  66) or acarbose (n  66). After a mean follow-up of 
3.9 years, significant reduction in the progression of CIMT 
was observed in the acarbose group versus placebo. CIMT 
increased by 0.02 p 0.07 mm in the acarbose group versus 
0.05 p 0.06 mm in the placebo group (P  0.027). The annual 
increase of CIMT was reduced by approximately 50% in 
the acarbose group versus placebo. CIMT progression was 
significantly related to acarbose intake on multiple linear 
regression analyses. As the primary effect of acarbose is on 
meal-time hyperglycemia, these data supported the impor-
tance of postprandial hyperglycemia.
A substudy was performed in 175 of 401 individuals 
with type 2 diabetes who had participated in an epidemio-
logical study to assess the relationship between postprandial 
hyperglycemia and surrogate markers of atherosclerosis.132 
The effects of repaglinide (n  88) and glyburide (n  87) 
on CIMT were compared after 12 months. Although, HbA
1c
 
improved to a comparable extent in both groups (0.9%), 
the postprandial glucose peak was lower in the repaglinide 
group (P  0.010). CIMT regression, defined as a decrease 
of 0.020 mm, was noted in a greater proportion of people 
on repaglinide (52%) than on glyburide 18% (P  0.010). 
Furthermore, the reduction in CIMT was associated with 
changes in postprandial but not fasting hyperglycemia. These 
data add to recent research, which suggests that postprandial 
hyperglycemic excursions may be more important than basal 
hyperglycemia in triggering atherosclerosis.
Antihypertensive agents and CIMT  
in people with diabetes
Post-hoc analyses of the association between antihyperten-
sive treatment and CIMT in the Troglitazone Atherosclerosis 
Regression Trial (TART), which assessed CIMT progres-
sion in adults with insulin-treated type 2 diabetes, found 
that higher systolic blood pressure was associated with a 
higher CIMT progression rate (P  0.03). Furthermore, 
anti-hypertensive treatment reduced this association in a 
duration-dependent manner (interaction P  0.035).133
Hosomi and colleagues did a prospective randomized 
clinical trial of 98 patients with type 2 diabetes who were 
randomized to either enalapril 10 mg/d (n  48) or to a con-
trol group (n  50) for 2 years.134 The enalapril-treated group 
was found to have reduced annual thickening of the common 
carotid arteries by 0.01 p 0.004 mm/y relative to the control 
group over the course of this study. These data concur with 
other data which showed that angiotensin-converting enzyme 
(ACE) inhibitors led to a reduction in myocardial infarction, 
stroke, cardiovascular death, total mortality, revasculariza-
tion, and overt nephropathy.135 Importantly, the D allele of the 
ACE gene has been shown to be an independent risk factor 
for coronary artery disease and with CIMT in individuals 
with type 2 diabetes.136,137
Lipid-lowering treatment and CIMT  
in people with diabetes
People with type 2 diabetes without prior cardiovascular events 
participated in the Stop Atherosclerosis in Native  Diabetics 
Study (SANDS) trial and were randomized to a  standard 
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group (target LDL cholesterol 2.6 mmol/L; non-HDL 
 cholesterol 3.4 mmol/L; systolic blood pressure 130 mmHg) 
and an aggressive group with tighter targets (target 
LDL cholesterol 1.8 mmol/L; non-HDL cholesterol 
2.6 mmol/L; systolic blood pressure 115 mmHg), and 
were treated with statins alone or statins plus ezetimibe.138 
The CIMT changes in both aggressive subgroups were com-
pared with changes in the standard subgroups (target LDL 
cholesterol 2.6 mmolL; non-HDL cholesterol 3.4 mmol/L; 
systolic blood pressure 130 mmHg). Within the aggressive 
group, mean CIMT at 36 months regressed from baseline simi-
larly in the ezetimibe (0.025 mm, range 0.05 to 0.003 mm) 
and nonezetimibe subgroups (0.012 mm, range 0.03 to 
0.008 mm) but progressed in the standard treatment arm 
(0.039 mm, range 0.02–0.06 mm; intergroup; P  0.0001). 
The authors concluded that reducing LDL cholesterol to 
aggressive targets resulted in similar regression of CIMT in 
patients who attained equivalent LDL cholesterol reductions 
from a statin alone or statin plus ezetimibe. CIMT increased 
in those achieving standard targets.
The Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol 6: HDL and LDL Treatment 
Strategies in Atherosclerosis (ARBITER 6-HALTS) study 
found that niacin resulted in a significant regression of mean 
and maximal CIMT whereas there was no significant change 
in CIMT in the ezetimibe-treated subgroup.139 Although not 
powered for clinical outcomes, there were more major car-
diovascular events in the ezetimibe arm than in the niacin arm 
(9 events vs 2 events, respectively; P  0.040).
Anti-platelet therapy and CIMT  
in people with diabetes
Kodama and colleagues followed up 150 people aged 52 
to 76 years with type 2 diabetes and without known CVD 
whose baseline CIMT was 1.1 mm.140 Antiplatelet agents 
(aspirin 81 mg/day, n  40; ticlopidine 200 mg/day, n  36; 
no drugs n  74) were administered. Individuals without 
anti-platelet agents had an annual progression of CIMT of 
0.067 mm/y. In contrast, low-dose aspirin or ticlopidine 
attenuated the progression of CIMT by 50% (0.033 mm and 
0.034 mm/year, respectively).
More recently, the prospective, randomized, open-label, 
blinded Diabetic Atherosclerosis Prevention by Cilostazol 
(DAPC) study showed that in people with type 2 diabetes 
suspected of peripheral artery disease, a phosphodiesterase 
inhibitor, cilostazol (100–200 mg/day) caused greater regres-
sion in the maximum and mean CIMT compared with aspirin 
(81–100 mg/day) during a 2-year observation period (mean left 
CIMT 0.043 p 0.182 vs 0.028 p 0.202 mm; P  0.004; 
mean right CIMT 0.024 p 0.182 vs 0.048 p 0.169 mm; 
P  0.001).141
Conclusions
Diabetes is associated with increased cardiovascular and 
cerebrovascular disease-related mortality. Early identification 
of people at higher risk can influence the treatment strategies 
to reduce the morbidity and mortality. CIMT measure-
ment is a relatively easy, noninvasive technique to identify 
atherosclerosis. People with diabetes have higher CIMT than 
the healthy population. CIMT increases in the presence of 
micro- and macrovascular complications of diabetes. Several 
treatment strategies in diabetes which have been shown to 
reduce diabetic complications also cause regression of CIMT. 
Thus, routine measurement of CIMT may add value to risk 
stratification and facilitate better use of various treatment 
strategies in people with diabetes.
Assessment of CIMT provides an excellent opportunity 
to evaluate the atherosclerotic risk in people with diabetes 
and can further be used to facilitate better use of various 
treatment strategies in people with diabetes. Further random-
ized studies would be required to assess the role of CIMT in 
predicting the development of various complications and how 
various available treatment strategies could be incorporated 
to influence the outcome.
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